Clinical trial
Unipolar Voltage-Guided Individualized Substrate Modification Combined With Pulsed Field Ablation-Based Pulmonary Vein Isolation Versus Pulmonary Vein Isolation Alone in Persistent Atrial Fibrillation: A Multicenter, Randomized, Open-Label, Superiority Trial
NCT07926854 is registered in ClinicalTrials.gov with China National Center for Cardiovascular Diseases as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Unipolar Voltage-Guided Individualized Substrate Modification Combined With Pulsed Field Ablation-Based Pulmonary Vein Isolation Versus Pulmonary Vein Isolation Alone in Persistent Atrial Fibrillation: A Multicenter, Randomized, Open-Label, Superiority Trial
- Lead sponsor
- China National Center for Cardiovascular Diseases
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- December 31, 2029
- Enrollment
- 294 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
atrial fibrillation (af)
Arms
As registered; 2 arms.
-
PFA-PVI Plus Individualized Substrate Modification
Pulsed field ablation (PFA)-based pulmonary vein isolation plus unipolar voltage-guided individualized substrate modification. Substrate modification is selected according to low-voltage area location and may include homogenization, box isolation, linear ablation, or a combination.
-
PFA-PVI Alone
Pulsed field ablation (PFA)-based pulmonary vein isolation alone, without substrate or prophylactic ablation.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Treatment Success at 12 Months After the Index Ablation Procedure
Freedom from documented atrial fibrillation, atrial tachycardia, or atrial flutter lasting more than 30 seconds after a 90-day blanking period while off class I/III antiarrhythmic drugs, allowing up to one repeat ablation within 6 months of the index procedure (1-2 procedures total). Patients who remain on class I/III antiarrhythmic drugs at 12 months are counted as treatment failures; missing primary outcome data are counted as treatment failures.
Lead sponsor's other trials
China National Center for Cardiovascular Diseases, most recent start first.
+264 more trials See the organization page
Similar trials
Same condition (Atrial Fibrillation) and phase, most recent start first.
+1,658 more trials See the condition page